EPO and anemia (phenotype): While recombinant human EPO has been a standard treatment for CKD-related anemia for over two decades, some studies have indicated that targeting higher hemoglobin concentrations with EPO treatment or higher ESA doses may elevate the risk of stroke, hypertension, thrombosis, and mortality [10, 24].